Prostate Cancer | Specialty

Evolving Role of Docetaxel in Metastatic Prostate Cancer

June 5th 2015

Clinical Trial Challenges in Metastatic CRPC

June 5th 2015

COU-AA-302: Abiraterone in Pre-Chemo CRPC

June 5th 2015

Role of AR-V7 in Multidisciplinary Prostate Cancer Care

June 5th 2015

Dr. Sandler on Docetaxel With Hormonal and Radiation Therapy in Prostate Cancer

June 2nd 2015

Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

First Effective Adjuvant Treatment Identified in High-Risk Prostate Cancer

May 31st 2015

Treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.

Dr. Kader on PGS Stratifying Baseline Risk of Prostate Cancer in PLCO Trial

May 28th 2015

A. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.

Dr. Mathew Hall on the Impact of PSA Screening Recommendations

May 27th 2015

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

2015 AUA Annual Meeting Highlights

May 22nd 2015

Radium-223 Survival Benefit Unaffected by Prior Hormonal Therapy

May 20th 2015

Prior treatment with abiraterone acetate or enzalutamide did not alter the survival benefit seen with radium-223 in men with advanced castration-resistant prostate cancer.

Dr. Shore on the TERRAIN Trial for Prostate Cancer

May 20th 2015

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses the results of the TERRAIN trial.

Lower CV Event Rate With Degarelix Versus LHRH Agonist Irrespective of Baseline Risk

May 20th 2015

Prostate cancer patients with different baseline cardiovascular risk had similar reductions in cardiovascular event rates when treated with the LHRH antagonist degarelix versus an LHRH agonist.

Dr. Cooperberg on Using Antagonists for Hormonal Therapy in Prostate Cancer

May 19th 2015

Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the efficacy of using an antagonist with hormone therapy in prostate cancer.

Combined Imaging Approach Effectively Detects Aggressive Prostate Cancer

May 18th 2015

The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.

Proteoglycan Assay Shows Potential as Adjunct to PSA Measurement

May 18th 2015

A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.

Sexual Function Scores Are Better After Robotic Versus Open Surgery for Prostate Cancer

May 18th 2015

Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.

Dr. Moul on Impact of Obesity in Active Surveillance

May 18th 2015

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.

Dr. O'Neil on Superior Quality of Life After Robotic Prostatectomy

May 18th 2015

Brock O'Neil, MD, physician, instructor in urologic surgery, Vanderbilt University, discusses a study that demonstrated evidence of superior quality of life after robotic assisted radical prostatectomy.

'Chilling Effect' Seen After USPSTF Recommends Against Routine PSA Testing

May 17th 2015

Since the USPSTF guideline on PSA screening the overall rate of PSA testing decreased by 50% among primary care physicians at Oregon Health & Science University.

Urine Assay Shows Promise as Test for High-Grade Prostate Cancer

May 17th 2015

A urine assay that targets expression of exosomal messenger RNA demonstrated high negative predictive value for high-grade prostate cancer in a study that validates the emerging test as a tool to help determine whether patients need initial biopsies.